The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours.
1 Low doses of carbidopa/levodopa (12.5 mg 1-alpha-methyl-dopahydrazine, 125 mg levodopa) were administered orally to 29 patients with tumours of the breast (16 with breast cancer, 13 with benign breast disease). 2 Plasma dopa response curves were similar in all the patients studied. 3 Prolactin and growth hormone showed similar responses to carbidopa/levodopa irrespective of age or diagnosis. 4 Prolactin showed an unusual reponse in four patients which has not previously been recorded.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000097:blood*; D002230:Carbidopa / Q000494:pharmacology*; D004295:Dihydroxyphenylalanine / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology*; D007980:Levodopa / Q000494:pharmacology*; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*; D013974:Thyroxine / Q000494:pharmacology; D013997:Time Factors
D006834:Hydrazines; D007980:Levodopa; D004295:Dihydroxyphenylalanine; D011388:Prolactin; D013006:Growth Hormone; D002230:Carbidopa; D013974:Thyroxine